^
Association details:
| Biomarker: | NTRK2 fusion |
|---|---|
| Cancer: | Ampulla of Vater Carcinoma |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
04/27/2023
Excerpt:
Ampullary Adenocarcinoma...Good PS….Targeted Systemic Therapies:...Useful in Certain Circumstances:...Entrectinib (if NTRK gene fusion positive).
